Jane Street Group LLC Has $1.49 Million Holdings in Evolus, Inc. (NASDAQ:EOLS)

Jane Street Group LLC increased its position in Evolus, Inc. (NASDAQ:EOLS) by 47.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 91,899 shares of the company’s stock after purchasing an additional 29,396 shares during the period. Jane Street Group LLC owned about 0.15% of Evolus worth $1,489,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in shares of Evolus in the 2nd quarter valued at about $43,000. Quarry LP purchased a new position in Evolus during the second quarter valued at approximately $54,000. Profund Advisors LLC acquired a new position in Evolus in the 2nd quarter valued at approximately $130,000. Point72 Asset Management L.P. purchased a new stake in Evolus in the 3rd quarter worth approximately $132,000. Finally, Arizona State Retirement System boosted its stake in shares of Evolus by 9.4% during the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after buying an additional 1,253 shares during the period. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Trading Down 2.3 %

Evolus stock opened at $11.09 on Friday. Evolus, Inc. has a one year low of $9.80 and a one year high of $17.82. The company’s fifty day moving average price is $13.46 and its two-hundred day moving average price is $13.73. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company has a market capitalization of $702.23 million, a price-to-earnings ratio of -12.19 and a beta of 1.27.

Analyst Upgrades and Downgrades

EOLS has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. Barclays lifted their price target on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a report on Monday, September 16th.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.